Journal of Clinical Endocrinology & Metabolism, Vol 60, 156-163, Copyright © 1985 by Endocrine Society

ARTICLES

Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women

A Gravanis, G Schaison, M George, J de Brux, PG Satyaswaroop, EE Baulieu and P Robel

The effects of the antiprogestin RU 486 on the human endometrium were investigated. Seventeen postmenopausal women were injected with estradiol (E2) benzoate (0.625 mg/day) for 15 days. Progesterone (P) (25 mg/day) and/or RU 486 (100 or 200 mg/day) were given to groups of 2- 3 women during the last 6 days of E2 benzoate treatment. Serial blood samples were drawn for the measurement of plasma E2, P, and LH and FSH. An endometrial biopsy was performed on the last day of treatment, and processed for histology or for assays of DNA polymerase alpha, E2- dehydrogenase (E2DH), and P receptor (PR). Treatment with E2 benzoate alone resulted in a marked decrease of plasma gonadotropins; in those patients who received either P, RU 486, or both, in addition to E2 benzoate, the concentrations of plasma LH and FSH were further decreased to premenopausal levels. In absence of glycerol, the affinity of RU 486 for the endometrial PR (Kd = 0.8 nM) was higher than that of P (Kd = 1.2 nM). Glycerol decreased markedly the affinity of RU 486, whereas the affinity of P for the PR was unchanged. RU 486 had negligible affinity for plasma transcortin. Either P or RU 486, but not both together, induced secretory changes in the endometrium as determined from histologic sections of tissue biopsies. Either P or RU 486 decreased DNA polymerase alpha and increased E2-DH activities in the endometrium. Unexpectedly, when P and RU 486 were given together. E2-DH activity remained at the level found in E2-treated women. In vitro cultures of proliferative endometrium treated with the synthetic progestagen R 5020 or with RU 486 also had increased E2-DH activity; RU 486 counteracted R 5020 effects. We conclude that, contrary to previous results with experimental animals, the anti-P RU 486 has some progestomimetic activity in humans under specific conditions. Paradoxically, when given together with P, RU 486 lost most of its progestomimetic activity in the endometrium and behaved as a pure antagonist.

This article has been cited by other articles:

				F. M. Horne and D. L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Hum. Reprod. Update, November 1, 2007; 13(6): 567 - 580. [Abstract] [Full Text] [PDF]

				N. Chabbert-Buffet, A. Pintiaux-Kairis, P. Bouchard, and on behalf of the VA2914 Study Group Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3582 - 3589. [Abstract] [Full Text] [PDF]

				S. J. Han, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley Distinct Temporal and Spatial Activities of RU486 on Progesterone Receptor Function in Reproductive Organs of Ovariectomized Mice Endocrinology, May 1, 2007; 148(5): 2471 - 2486. [Abstract] [Full Text] [PDF]

				N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307. [Abstract] [Full Text] [PDF]

				D.T. Baird, A. Brown, H.O.D. Critchley, A.R. Williams, S. Lin, and L. Cheng Effect of long-term treatment with low-dose mifepristone on the endometrium Hum. Reprod., January 1, 2003; 18(1): 61 - 68. [Abstract] [Full Text] [PDF]

				X. Qiu, X. Sun, A. Christow, B. Stabi, and K. Gemzell-Danielsson The effect of mifepristone on the expression of insulin-like growth factor binding protein-1, prolactin and progesterone receptor mRNA and protein during the implantation phase in human endometrium Mol. Hum. Reprod., November 1, 2002; 8(11): 998 - 1004. [Abstract] [Full Text] [PDF]

				K. CHWALISZ, R. GARG, R. M. BRENNER, G. SCHUBERT, and W. ELGER Selective Progesterone Receptor Modulators (SPRMs): A Novel Therapeutic Concept in Endometriosis Ann. N.Y. Acad. Sci., March 1, 2002; 955(1): 373 - 388. [Abstract] [Full Text] [PDF]

				S. A. Hild, J. R.Reel, L. H.Hoffman, and R. P.Blye CDB-2914: Anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits Hum. Reprod., April 1, 2000; 15(4): 822 - 829. [Abstract] [Full Text] [PDF]

				R.R. Greb, L. Kiesel, A.K. Selbmann, M. Wehrmann, G.D. Hodgen, A.L. Goodman, and D. Wallwiener Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium Hum. Reprod., January 1, 1999; 14(1): 198 - 206. [Abstract] [Full Text] [PDF]

				K. Wiedemann, C. J. Lauer, M. Hirschmann, K. Knaudt, and F. Holsboer Sleep-endocrine effects of mifepristone and megestrol acetate in healthy men Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E139 - E145. [Abstract] [Full Text] [PDF]

				A. Omigbodun, P. Ziolkiewicz, C. Tessler, J. R. Hoyer, and C. Coutifaris Progesterone Regulates Osteopontin Expression in Human Trophoblasts: A Model of Paracrine Control in the Placenta? Endocrinology, October 1, 1997; 138(10): 4308 - 4315. [Abstract] [Full Text] [PDF]

				K. J. Modarress, J. Opoku, M. Xu, N. J. Sarlis, and S. S. Simons Jr. Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity J. Biol. Chem., September 19, 1997; 272(38): 23986 - 23994. [Abstract] [Full Text] [PDF]

				E. Xiao, L. Xia-Zhang, D. Shanen, and M. Ferin Tonic Support of Luteinizing Hormone Secretion by Adrenal Progesterone in the Ovariectomized Monkey Replaced with Midfollicular Phase Levels of Estradiol J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2233 - 2238. [Abstract] [Full Text] [PDF]

				I. M. Spitz and C.W. Bardin Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action N. Engl. J. Med., August 5, 1993; 329(6): 404 - 412. [Full Text]

				E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science, September 22, 1989; 245(4924): 1351 - 1357. [Abstract] [PDF]